Amifostine: A novel cytoprotective agent

Cancer Practice

Volumn 5, Issue 3, 1997, Pages 189-191

  McCauley, Dayna L ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE;

CHILL; DRUG COST; DRUG USE; HICCUP; HUMAN; HYPOCALCEMIA; HYPOTENSION; MALIGNANT NEOPLASTIC DISEASE; REVIEW; TREATMENT INDICATION;

AMIFOSTINE; DRUG COSTS; HUMANS; RADIATION-PROTECTIVE AGENTS;

EID: 0030994148     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Davidson DE, Grenan MM, Sweeney TR. Biological characteristics of some improved radioprotectors. In: Brady LW, ed. Radiation Sensitizers: Their Use in the Clinical Management of Cancer. New York: Masson; 1980:309.
2. Ethyol (Amifostine, U.S. Bioscience Inc. and Alza Pharmaceuticals) Injection Prescribing Information. Package Insert. Palo Alto, CA: Alza Pharmaceuticals; West Conshohocken, PA: U.S. Bioscience Inc; March 1996.
3. Capizzi RL. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996; 23(suppl 8):2-17.
4. Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin Oncol 1996; 23(suppl 8):18-22.
5. Kataoka Y, Perrin J, Hunter N, Milas L, Grdina DJ. Antimutagenic effects of amifostine: clinical implications. Semin Oncol 1996; 23(suppl 8):53-57.
6. Capizzi RL, Wang LM, Taylor C, et al. Protracted exposure to amifostine improved the therapeutic index of paclitaxel. Proc Am Soc Clin Oncol 1996; 15:498 (abstract).
7. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101-2112.
8. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
9. DiPaola R, Rodriguez R, Recio A, et al. A phase I study of amifostine and paclitaxel in patients with advanced malignancies. Proc Am Soc Clin Oncol 1996; 15:488 (abstract).
10. Budd GT, Bukowski RM, Adelstein D, et al. Mature results of a randomized trial of carboplatin (C) and amifostine (A) vs. C alone in patients (pts) with advanced malignancies. Proc Am Soc Clin Oncol 1996; 15:532 (abstract).
11. Betticher DC, Anderson H, Ranson M, Meely K, Oster W, Thatcher N. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomized phase II study. Br J Cancer 1995; 72:1551-1555.
12. Shpall EJ, Stemmer SM, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994; 83:3132-3137.
13. Klingerman MM, Turrisi AT, Urtasum RC, et al. Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1988: 14:1119-1122.
14. Liu T, Liu Y, He S, et al. The use of radiation with or without amifostine in advanced rectal cancer. Cancer 1992; 69:2820-2825.
15. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996;14: 1913-1921.
16. Glover D, Glick J, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5:574-578.
17. Ryan SV, Carrithers SL, Parkinson SJ, et al. Hypotensive mechanisms of amifostine. J Clin Pharmacol 1996; 36:365-373.
18. Schucter LM. Guidelines for the administration of amifostine. Semin Oncol 1996; 23(suppl 8):40-43.